Idm Pharma, Inc. Watch

from 8-K 11 pages Confidential Timothy P. Walbert Idm Pharma, Inc. 9 Parker, Suite 100 Irvine, Ca 92618 Dear Mr. Walbert

from SC 13G/A 1 page Agreement Pursuant to Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, the Undersigned Hereby Agree That Only One Statement Containing the Information Required by Schedule 13g Need Be Filed With Respect to the Ownership by Each of the Undersigned of Shares of Common Stock of Epimmune Inc. This Agreement May Be Executed in Any Number of Counterparts, Each of Which Shall Be Deemed an Original. Executed This 17th Day of February, 2004

from S-1/A ~20 pages Underwriting agreement

from SC 13D ~20 pages Stock Purchase Agreement

from SC 13D 1 page <page> 1 Exhibit 1 Joint Filing Agreement in Accordance With Rule 13d-1(f) Under the Securities Exchange Act of 1934, as Amended, Each of the Persons Named Below Agrees to the Joint Filing of a Statement on Schedule 13d (Including Amendments Thereto) With Respect to the Common Stock, Par Value $.01 Per Share, of Cytel Corporation, a Delaware Corporation, and Further Agrees That This Joint Filing Agreement Be Included as an Exhibit to Such Filings; Provided That, as Contemplated by Section 13d-1(f)(l)(ii), No Person Shall Be Responsible for the Completeness or Accuracy of the Information Concerning the Other Persons Making the Filing, Unless Such Person Knows or Has Reason to Believe That Such Information Is Inaccurate. This Joint Filing May Be Executed in Any Number of Counterparts, All of Which Together Shall Constitute One and the Same Instrument. G. D. Searle & Co. By: /S/ Richard U. De Schutter Title: Chief Executive Officer Monsanto Company By: /S/ Robert B. Hoffman Title: Chief Financial Officer